Jian Yu

Professor of Medicine

Image of Jian Yu
Is this your profile? Click to edit

Overview

My research explores mechanistic coupling of intestinal stem cell injury with regeneration, focusing on cancer driver-dependent regulation of cell death, stress adaptation, and immunologic outcomes. Our long-term goal is to identify novel targets and agents for colon cancer prevention and treatment through stem cell and niche normalization and epithelial barrier longevity. I have been active in teaching and mentoring students, postdoctoral fellows, and junior faculty.

Secondary appointment: Professor of Cancer Biology

Publications
-My NCBI
https://www.ncbi.nlm.nih.gov/myncbi/jian.yu.1/bibliography/public/
-Google Scholar
https://scholar.google.com/citations?user=yXODGQYAAAAJ&hl=en&authuser=1

Awards

  • Johns Hopkins University School of Medicine: Michael A. Shanoff Research Excellence Award, 2001
  • The Flight Attendant Medical Research Institute: Young Clinical Scientist Award, 2003
  • The Hillman Foundation: The Hillman Fellow of Innovative Cancer Research, 2004
  • The Alliance for Cancer Gene Therapy: Young Investigator Award, 2005
  • University of Pittsburgh Cancer Institute: Junior Scholar Award, 2008
  • American Cancer Society: Research Scholar Award, 2010
  • University of Pittsburgh: Innovator Award, 2011

Education and Training

  • Sichuan University, Chengdu, China — BS — 07/1991 — Chemistry
  • Johns Hopkins University, Baltimore, USA — PhD — 05/2001 — Human Genetics and Molecular Biology
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins , Baltimore, USA — Fellowship, postdoctoral — 06/2002 — Oncology

Research Funding

  • LR-IL-22 for Mitigation and Management of Radiation Injuries
    NIH/NIAID · U01 AI172885 · Dec 1, 2022 – Nov 30, 2027 · Role: Co-Investigator
  • STING-dependent Intestinal Regeneration upon Radiation Injury
    NIH/NCI · R01CA260900 · Feb 9, 2022 – Jan 31, 2027 · Role: Principal Investigator
  • STING-dependent Intestinal Regeneration upon Radiation Injury
    NIH · R01CA260900 · Feb 7, 2022 – Aug 31, 2027 · Role: Principal Investigator
  • BET degraders for improving colorectal cancer therapy
    NIH/NCI · R01CA248112 · Apr 1, 2021 – Mar 31, 2026 · Role: Co-Investigator
  • Targeting defective necroptosis in colorectal cancer
    NIH · R01CA247231 · Dec 1, 2019 – Mar 31, 2025 · Role: Co-Principal Investigator
  • Targeting defective necroptosis in colorectal cancer
    NIH/NCI · R01CA247231 · Dec 1, 2019 – Nov 30, 2024 · Role: Co-Principle Investigator, MPI
  • Translation addiction and targeting in colon cancer
    NIH/NCI · R01CA215481 · Jan 1, 2018 – Mar 31, 2023 · Role: Principle Investigator
  • Translation addiction and targeting in colon cancer
    NIH · R01CA215481 · Jan 1, 2018 – Mar 31, 2023 · Role: Principal Investigator
  • Intestinal Stem Cell Survival and Renewal Coordinately Regulated by PUMA and p21
    NIH · U01DK085570 · Sep 30, 2009 – Aug 31, 2015 · Role: Principal Investigator
  • Role of PUMA in EGFR targeted therapy in HNSCC
    NIH · R01CA129829 · Aug 1, 2008 – May 31, 2014 · Role: Principal Investigator

Research Keywords

  • cell death
  • stress adaptation
  • intestinal stem cell
  • colon cancer
  • inflammation

Publications

  • The State-of-the-Art PET Tracers in Glioblastoma and High-grade Gliomas and Implications for Theranostics. PET Clin. 2025 Jan; 20(1):147-164.. View in PubMed
  • Renal Transplant Anastomotic Pseudoaneurysm and Stenosis at the Proximal Transplant Renal Artery and Worse Renal Blood Flow After Stent Placement. Clin Nucl Med. 2024 Sep 01; 49(9):e447-e450.. View in PubMed
  • mTOR inhibition suppresses Myc-driven polyposis by inducing immunogenic cell death. Oncogene. 2023 06; 42(24):2007-2016.. View in PubMed
  • Targeting Myc-driven stress addiction in colorectal cancer. Drug Resist Updat. 2023 07; 69:100963.. View in PubMed
  • Release of Interferon-β (IFN-β) from Probiotic Limosilactobacillus reuteri-IFN-β (LR-IFN-β) Mitigates Gastrointestinal Acute Radiation Syndrome (GI-ARS) following Whole Abdominal Irradiation. Cancers (Basel). 2023 Mar 08; 15(6).. View in PubMed
  • Inhibition of multiple CDKs potentiates colon cancer chemotherapy via p73-mediated DR5 induction. Oncogene. 2023 03; 42(12):869-880.. View in PubMed
  • Synthetical lethality of Werner helicase and mismatch repair deficiency is mediated by p53 and PUMA in colon cancer. Proc Natl Acad Sci U S A. 2022 12 20; 119(51):e2211775119.. View in PubMed
  • Dual inhibition of BET and HAT/p300 suppresses colorectal cancer via DR5- and p53/PUMA-mediated cell death. Front Oncol. 2022; 12:1018775.. View in PubMed
  • Lactobacillus reuteri Releasing IL-22 (LR-IL-22) Facilitates Intestinal Radioprotection for Whole-Abdomen Irradiation (WAI) of Ovarian Cancer. Radiat Res. 2022 07 01; 198(1):89-105.. View in PubMed
  • CDK4/6 Inhibition Suppresses p73 Phosphorylation and Activates DR5 to Potentiate Chemotherapy and Immune Checkpoint Blockade. Cancer Res. 2022 04 01; 82(7):1340-1352.. View in PubMed